Biocon’s path-breaking work in novel biologics and novel targets in large molecules has seen significant results in oncology and immunology. The novel biologics portfolio includes both, in-house as well as partnered products.
CONTACT
Group Companies
NOVEL BIOLOGICS
Enabling cutting edge therapies
Bicara Therapeutics, a clinical-stage biotechnology company based in Boston, U.S., anchors the development of a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara has access to the thriving innovation ecosystem in the U.S. enabling it to accelerate the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru is accelerating the development of cutting-edge therapies to improve outcomes for cancer patients.
global innovations
In-house research capabilities
Access to novel IP, therapeutic modalities, in-vivo and in-vitro models
Toxicology studies
Early regulatory filings
Academic collaborations
novel assets
Monoclonal antibodies against novel targets like CD6, and established targets like EGFR
Bispecific fusion antibodies that explore the role of checkpoint inhibitors
Novels Biologics
BUSINESS INTENT
Create Market Leadership in Innovation
PIPELINE
mAbs against targets like CD6, EGFR; bi-specific fusion mAbs
POTENTIAL
To change the treatment paradigm in inflammation and immunology
Biocon & Novels
We are the pioneers in developing, manufacturing and launching BIOMAb-EGFR®, India’s first indigenously produced novel monoclonal antibody for the treatment of head and neck cancer; and ALZUMAb®, the world’s first novel anti-CD6 monoclonal antibody in India, for psoriasis.
Novels In Pipeline
Our novel biologics under clinical development focus on treatments in autoimmune/ inflammation and oncology. These represent a combination of early and advanced stage assets.
Know more
about us
FINANCIAL CALENDAR
KEY THERAPEUTIC AREAS
OUR KEY PRIORITIES
BOARD OF DIRECTORS
